



# Philippines: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility - Additional Financing

Project Name	Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility - Additional Financing
Project Number	54171-004
Country	Philippines
Project Status	Approved
Project Type / Modality of Assistance	Loan
Source of Funding / Amount	<div>Loan 4163-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility - Additional Financing</div> <div>Ordinary capital resources US\$ 250.00 million</div> <div>Loan 8413-PHI: Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility - Additional Financing</div> <div>Asian Infrastructure Investment Bank US\$ 250.00 million</div>
Strategic Agendas	Inclusive economic growth Regional integration
Drivers of Change	Partnerships
Sector / Subsector	Health - Disease control of communicable disease
Gender Equity and Mainstreaming	Effective gender mainstreaming
Description	The additional financing of the Second Health System Enhancement to Address and Limit COVID-19 under the Asia Pacific Vaccine Access Facility (HEAL2-AF) builds on the original project and will expand the Philippines procurement and deployment of coronavirus disease (COVID-19) vaccines. It will support the governments procurement of at least 40 million additional doses of COVID-19 vaccines for eligible children, and third and booster shots for the wider population. <sup>2</sup> The HEAL2-AF complements the Asian Development Bank (ADB) Health System Enhancement to Address and Limit COVID-19 (HEAL) project, which supports the government's COVID-19 response.
Project Rationale and Linkage to Country/Regional Strategy	On 11 March 2021, ADB approved a regular loan of \$400 million for HEAL2 to be financed from its ordinary capital resources. <sup>4</sup> HEAL2 is cofinanced by AIIB with a loan of \$300 million, partially administered by ADB. HEAL2 provided the Government of the Philippines with timely financing for procurement of safe and effective vaccines and related logistics, based on an agreed list of eligible expenditures. In total, with a major change in scope of HEAL (footnote 3), ADB has provided \$425 million for COVID-19 vaccine procurement and deployment.
Impact	Impacts the Project is Aligned with Health system performance in addressing public health outbreaks improved (National Objectives for Health, Philippines 2017 2022) <sup>a</sup> Protection of the public and reduction of COVID-19-related morbidity and mortality fostered (National COVID-19 Vaccine Roadmap) <sup>b</sup> Economic growth and citizens' confidence restored (ADB's Support to Enhance COVID-19 Vaccine) <sup>c</sup>
Project Outcome	
Description of Outcome	Priority populations vaccinated against COVID-19.
Progress Toward Outcome	
Implementation Progress	
Description of Project Outputs	1. COVID-19 vaccines efficiently and effectively delivered.
Status of Implementation Progress (Outputs, Activities, and Issues)	
Geographical Location	Nation-wide
Safeguard Categories	
Environment	C
Involuntary Resettlement	C
Indigenous Peoples	C
Summary of Environmental and Social Aspects	

Environmental Aspects
Involuntary Resettlement
Indigenous Peoples
Stakeholder Communication, Participation, and Consultation
During Project Design
During Project Implementation

Responsible ADB Officer	Tanaka, Sakiko
Responsible ADB Department	Southeast Asia Department
Responsible ADB Division	Human and Social Development Division, SERD
Executing Agencies	Department of Health Tayuman Street Sta. Cruz, Manila Philippines

Timetable	
Concept Clearance	-
Fact Finding	21 Sep 2021 to 24 Sep 2021
MRM	22 Oct 2021
Approval	13 Dec 2021
Last Review Mission	-
Last PDS Update	13 Dec 2021

## Loan 4163-PHI

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	299.37	Cumulative Contract Awards			
ADB	250.00	-	0.00	0.00	%
Counterpart	49.37	Cumulative Disbursements			
Cofinancing	0.00	-	0.00	0.00	%

## Loan 8413-PHI

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	250.00	Cumulative Contract Awards			
ADB	0.00	-	0.00	0.00	%
Counterpart	0.00	Cumulative Disbursements			
Cofinancing	250.00	-	0.00	0.00	%

Project Page	<a href="https://www.adb.org/projects/54171-004/main">https://www.adb.org/projects/54171-004/main</a>
Request for Information	<a href="http://www.adb.org/forms/request-information-form?subject=54171-004">http://www.adb.org/forms/request-information-form?subject=54171-004</a>
Date Generated	14 December 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.